An increase in the incidence of physician-diagnosed diabetes with rosuvastatin in Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) published recently revived clinical interest in the effects of statins on glycemic control. The study showed that, after almost 2 years of follow-up in men and women with elevated levels of high-sensitivity C-reactive protein but average LDL cholesterol, rosuvastatin therapy was associated with a mild but significant increase in the identification of new-onset diabetes (3% in the statin arm, 2.4% in the placebo arm; P < 0.01) (1). The potential association between statin use and new-onset diabetes gained attention in 2001 when a post hoc analysis of another primary prevention statin trial, the West of Scotland Coronary Prevention Study (WOSCOPS), reported that treatment with pravastatin decreased the hazard of developing type 2 diabetes by 30% (hazard ratio 0.7 [95% CI 0.5–0.99]; P = 0.042) (2). These seemingly contradictory findings flank results from four other statin trials that failed to uncover a significant relationship between statin use and incident type 2 diabetes when the latter was evaluated as a tertiary end point (3–6). In this issue of Diabetes Care , Rajpathak et al. (7) bring together six randomized placebo-controlled trials to explore diabetes risk with statins using a meta-analytical approach. The authors found that, if they included all six studies in the analysis (a total of 2,082 cases of incident diabetes in 57,593 study participants), there was no significant association between statin use and the development of type 2 diabetes (relative risk 1.06 [95% CI 0.93–1.25]). On the other hand, …